MCID: CYT004
MIFTS: 34

Cytomegalic Inclusion Disease

Categories: Rare diseases

Aliases & Classifications for Cytomegalic Inclusion Disease

MalaCards integrated aliases for Cytomegalic Inclusion Disease:

Name: Cytomegalic Inclusion Disease 53
Cytomegalic Inclusion Body Disease 53 54 73
Giant Cell Inclusion Disease 53 54
Cytomegalovirus Infections 73
Cibd 53

Classifications:



External Ids:

Summaries for Cytomegalic Inclusion Disease

NINDS : 54 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalic Inclusion Disease, also known as cytomegalic inclusion body disease, is related to pneumonia and cerebritis, and has symptoms including fever and pruritus. The drugs Foscarnet and Ganciclovir have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and eye.

Related Diseases for Cytomegalic Inclusion Disease

Diseases related to Cytomegalic Inclusion Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 pneumonia 10.2
2 cerebritis 10.2
3 leukemia 10.1
4 cytomegalovirus infection 10.1
5 toxoplasmosis 10.1
6 aspergillosis 10.0
7 hepatitis 10.0
8 thrombocytopenia 10.0
9 lymphoma 10.0
10 neonatal jaundice 10.0
11 rhinitis 10.0
12 childhood leukemia 10.0
13 herpes simplex 10.0
14 chorioretinitis 10.0
15 macroglobulinemia 10.0
16 abdominal wall defect 9.9
17 anemia, autoimmune hemolytic 9.8
18 wiskott-aldrich syndrome 9.8
19 aging 9.8
20 acute leukemia 9.8
21 adult t-cell leukemia 9.8
22 burns 9.8
23 glomerulonephritis 9.8
24 hemolytic anemia 9.8
25 ulcerative colitis 9.8
26 colitis 9.8
27 porencephaly 9.8
28 inguinal hernia 9.8
29 mucositis 9.8
30 siderosis 9.8
31 osteomalacia 9.8
32 fiedler's myocarditis 9.8
33 hypoparathyroidism 9.8
34 disseminated intravascular coagulation 9.8
35 pneumocystosis 9.8
36 uveitis 9.8
37 urethritis 9.8
38 cholestasis 9.8
39 candidiasis 9.8
40 intrahepatic cholestasis 9.8
41 retinitis 9.8
42 t-cell leukemia 9.8
43 myocarditis 9.8
44 malignant histiocytosis 9.8
45 hodgkin's granuloma 9.8
46 lymphosarcoma 9.8
47 rubella 9.8
48 meningitis 9.8
49 encephalitis 9.8
50 congenital cytomegalovirus 9.8

Graphical network of the top 20 diseases related to Cytomegalic Inclusion Disease:



Diseases related to Cytomegalic Inclusion Disease

Symptoms & Phenotypes for Cytomegalic Inclusion Disease

UMLS symptoms related to Cytomegalic Inclusion Disease:


fever, pruritus

Drugs & Therapeutics for Cytomegalic Inclusion Disease

Drugs for Cytomegalic Inclusion Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63585-09-1, 4428-95-9 3415
2
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
4
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113852-37-2 60613
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
9
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
10
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128794-94-5 5281078
11
Acyclovir Approved Phase 4,Phase 3,Phase 2,Not Applicable 59277-89-3 2022
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
13
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
14
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
17
Infliximab Approved Phase 4 170277-31-3
18
Basiliximab Approved, Investigational Phase 4,Not Applicable 152923-56-3, 179045-86-4
19
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
20
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57-66-9 4911
21
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
22
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
23
Pancrelipase Approved, Investigational Phase 4,Not Applicable 53608-75-6
24
Azathioprine Approved Phase 4 446-86-6 2265
25 tannic acid Approved, Nutraceutical Phase 4
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
28
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
29
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4408-78-0 546
30 triamcinolone acetonide Phase 4
31 Prednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 glucocorticoids Phase 4,Phase 3
33 Methylprednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Gastrointestinal Agents Phase 4,Phase 1,Not Applicable
38 Neuroprotective Agents Phase 4
39 Cyclosporins Phase 4,Phase 3,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2
41 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Triamcinolone diacetate Phase 4
43 Triamcinolone hexacetonide Phase 4
44 Hormones Phase 4,Phase 3,Phase 2
45 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
50 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 364)
# Name Status NCT ID Phase Drugs
1 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
3 PTH - Preemptive Treatment for Herpesviridae Unknown status NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
4 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
5 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
8 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
9 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
10 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
11 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
12 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
13 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
14 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
15 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
16 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
17 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
18 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
19 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
20 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
21 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
22 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
23 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
24 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
25 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
26 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
27 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
28 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
29 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
30 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
31 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Active, not recruiting NCT02328963 Phase 4 Everolimus;mycophenolic acid
32 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Active, not recruiting NCT02550639 Phase 4
33 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Active, not recruiting NCT01552369 Phase 4 Valganciclovir
34 Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients Enrolling by invitation NCT01817699 Phase 4
35 Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients Not yet recruiting NCT02453867 Phase 4 Tacrolimus;mycophenolate;Steroids
36 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
37 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
38 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
39 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
40 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
41 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
42 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
43 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 Letermovir;Placebo
44 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
45 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
46 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir
47 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
48 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
49 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
50 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation Completed NCT00372229 Phase 3 Pre-emptive therapy;valganciclovir [Valcyte]

Search NIH Clinical Center for Cytomegalic Inclusion Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Cytomegalic Inclusion Disease

Anatomical Context for Cytomegalic Inclusion Disease

MalaCards organs/tissues related to Cytomegalic Inclusion Disease:

41
Kidney, T Cells, Eye, Liver, Breast, Bone, Testes

Publications for Cytomegalic Inclusion Disease

Articles related to Cytomegalic Inclusion Disease:

(show top 50) (show all 217)
# Title Authors Year
1
Cytomegalic Inclusion Disease caused by Cytomegalovirus Infection in the Salivary Glands ofA an African Hedgehog (Atelerix arbiventris). ( 29169627 )
2017
2
Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. ( 10740207 )
2000
3
A fatal case of congenital cytomegalic inclusion disease following recurrent maternal infection. ( 8590396 )
1995
4
Temporal bone histopathology 14 years after cytomegalic inclusion disease: a case study. ( 8395628 )
1993
5
Disseminated cutaneous cytomegalic inclusion disease resembling prurigo nodularis in a HIV-infected patient: a case report and literature review. ( 7964230 )
1993
6
Cytomegalic inclusion disease presenting acute intrahepatic cholestasis. ( 1338619 )
1992
7
Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involving the brain. ( 1846993 )
1991
8
Salivary gland oncocytes in African hedgehogs (Atelerix albiventris) mimicking cytomegalic inclusion disease. ( 1655834 )
1991
9
Successful treatment of disseminated cutaneous cytomegalic inclusion disease associated with Hodgkin's disease. ( 1847957 )
1991
10
A viral infection causing cytomegalic inclusion disease in the renal epithelium of the platypus (Ornithorhynchus anatinus). ( 2154629 )
1990
11
Spontaneous disseminated cytomegalic inclusion disease in an ageing laboratory mouse. ( 2843585 )
1988
12
Evaluation of diagnostic criteria for mucosal cytomegalic inclusion disease in the acquired immune deficiency syndrome. ( 2825515 )
1987
13
Glomerulonephritis in congenital cytomegalic inclusion disease. ( 3019866 )
1986
14
Reactivation of congenital cytomegalic inclusion disease in an infant with HTLV-III associated immunodeficiency: a CT-pathologic correlation. ( 3009568 )
1986
15
The incidence of cytomegalic inclusion disease (CID) in an obstetric teaching hospital, 1975-1984. ( 3002314 )
1985
16
Disseminated intravascular coagulation induced by generalized cytomegalic inclusion disease during steroid therapy for polymyositis. ( 2994360 )
1985
17
Cytomegalic inclusion disease after recurrent maternal infection. ( 2865630 )
1985
18
Sudden infant death with congenital cytomegalic inclusion disease. ( 6324573 )
1984
19
Two-dimensional ultrasonography of the brain: its diagnostic usefullness in herpes simplex encephalitis and cytomegalic inclusion disease. ( 6311039 )
1983
20
Neonatal cytomegalic inclusion disease in a set of twins one member of whom was a hydropic stillbirth the other completely uninfected. Case report. ( 6299328 )
1983
21
Computed tomography in the diagnosis of congenital cytomegalic inclusion disease. ( 6293102 )
1982
22
Cytomegalic inclusion disease diagnosed endoscopically. ( 6257456 )
1981
23
Cytomegalic inclusion disease of the skin. ( 6261699 )
1981
24
Generalized cytomegalic inclusion disease in neonates and infants. ( 6249068 )
1980
25
An electron microscopic study of cytomegalic inclusion body disease in the swine. ( 6268891 )
1980
26
Adult cytomegalic inclusion disease. ( 6259726 )
1980
27
Adult pulmonary cytomegalic inclusion disease: report of a case. ( 6244337 )
1980
28
Adult T-cell leukemia with generalized cytomegalic inclusion disease and pneumocystis carinii pneumonia. ( 233285 )
1979
29
Osseous lesions and pathologic fractures in congenital cytomegalic inclusion disease: report of a case. ( 231493 )
1979
30
Cytomegalic inclusion disease: a study of fifty-five autopsies. ( 226645 )
1979
31
Hepatic calcification in congenital cytomegalic inclusion disease. ( 205645 )
1978
32
Noncirrhotic portal fibrosis following neonatal cytomegalic inclusion disease. ( 213550 )
1978
33
Pathology of cytomegalic inclusion body disease in swine. ( 192934 )
1977
34
Calcification in liver associated with congenital cytomegalic inclusion disease. ( 190372 )
1977
35
The otologic manifestations of cytomegalic inclusion disease - a case report. ( 193219 )
1977
36
Fatal cytomegalic inclusion disease. Associated skin manifestations in a renal transplant patient. ( 201217 )
1977
37
Ocular cytomegalic inclusion disease in the adult. ( 214905 )
1977
38
Generalized porcine cytomegalic inclusion disease: distribution of cytomegalic cells and virus. ( 178692 )
1976
39
Pseudoglioma and cytomegalic inclusion disease. ( 192400 )
1976
40
Disseminated cytomegalic inclusion disease in an adult with cirrhosis of liver and review of literatures. ( 190080 )
1976
41
Cytomegalic inclusion disease with petechiae and thrombocytopenia at birth. ( 166764 )
1975
42
Unusual roentgenological findings in cytomegalic inclusion body disease: large and circumscribed calcareous deposits of the basal ganglia and scattered calcifications of the parieto-occipital cortex. ( 184419 )
1975
43
Bone changes in congenital cytomegalic inclusion disease. ( 165786 )
1975
44
An autopsy case of generalized cytomegalic inclusion disease associated with Pneumocystis carinii pneumonia. ( 173920 )
1975
45
Cytomegalic inclusion disease in the east African headgehog. ( 167206 )
1975
46
Fecal excretion of cytomegalovirus in disseminated cytomegalic inclusion disease. ( 4365949 )
1974
47
An autopsy case of isolated myocarditis probably associated with infectious mononucleosis and disseminated cytomegalic inclusion disease. ( 4365594 )
1974
48
Unusual glomerular change in cytomegalic inclusion disease. ( 4374799 )
1974
49
Massive fetal ascites, urethral atresia, and cytomegalic inclusion disease. ( 4365977 )
1974
50
Persistent albuminuria and meningitis caused by congenital cytomegalovirus infection. A case report of cytomegalic inclusion disease. ( 4369003 )
1973

Variations for Cytomegalic Inclusion Disease

Expression for Cytomegalic Inclusion Disease

Search GEO for disease gene expression data for Cytomegalic Inclusion Disease.

Pathways for Cytomegalic Inclusion Disease

GO Terms for Cytomegalic Inclusion Disease

Sources for Cytomegalic Inclusion Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....